Porcupine inhibition is a promising pharmacological treatment for severe sclerosteosis pathologies

Abstract

Sclerosteosis, an ultra-rare disorder characterised by high bone mass (HBM) and skeletal overgrowth, leads to facial paralysis, hearing loss and raised intracranial pressure, which is currently managed only through high-risk surgery. Sclerosteosis is caused by SOST mutations and loss of functional sclerostin, a protein that suppresses osteogenesis by antagonising Wnt/β-catenin signalling. Herein, using in vitro and in vivo approaches, we explore whether LGK974, another potent Wnt inhibitor that targets porcupine (PORCN, Wnt-specific acyltransferase), is a promising sclerosteosis therapeutic. In vitro assays showed that 100 nmol/L LGK974 significantly reduced osteoblast alkaline phosphatase (ALP) activity/mineralisation, decreased Wnt/osteoblast marker (Axin2, Runx2 and Ocn) expression, and downregulated ossification and the Wnt signalling pathway, without affecting osteoclast numbers/resorption. To assess in vivo effects, 6-week-old male and female Sost deficient (Sost^-/-) mice received LGK974 for 4 weeks and right hindlimbs were subjected to 20 N peak loading to assess mechanoadaptive interactions. µCT revealed significant reductions in vertebral trabecular number and lower cortical bone volume in loaded and non-loaded tibiae in male and female LGK974-treated Sost^-/- mice. Interestingly, the target engagement biomarker Axin2 was only significantly reduced in male vertebrae, which may indicate differences in male and female response to LGK974. This study also shows that PORCN inhibition may effectively limit characteristic HBM and skeletal overgrowth in sclerosteosis patients at sites with severe pathology.

Keywords

Medical and Health Sciences / Clinical Sciences

References

[1] BergenDJM, et al. . High bone mass disorders: new insights from connecting the clinic and the bench. J. Bone Miner. Res., 2023, 38: 229-247.

[2] JhaS, ChapmanM, RoszkoK. When low bone mineral density and fractures is not osteoporosis. Curr. Osteoporos. Rep., 2019, 17: 324-332.

[3] van LieropAH, Appelman-DijkstraNM, PapapoulosSE. Sclerostin deficiency in humans. Bone, 2017, 96: 51-62.

[4] StuartAS, et al. . Sclerosteosis. Neurology, 1983, 33: 267.

[5] KimCA, et al. . A known SOST gene mutation causes sclerosteosis in a familial and an isolated case from Brazilian origin. Genet. Test., 2008, 12: 475-479.

[6] BalemansW, CleirenE, SiebersU, HorstJ, Van HulW. A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene. Bone, 2005, 36: 943-947.

[7] BelkhribchiaMR, ColletC, LaplancheJ-L, HassaniR. Novel SOST gene mutation in a sclerosteosis patient from Morocco: A case report. Eur. J. Med. Genet., 2014, 57: 133-137.

[8] PitersE, et al. . First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function. Hum. Mutat., 2010, 31: E1526-E1543.

[9] YagiH, TakagiM, HasegawaY, KayseriliH, NishimuraG. Sclerosteosis (craniotubular hyperostosis-syndactyly) with complex hyperphalangy of the index finger. Pediatr. Radiol., 2015, 45: 1239-1243.

[10] TholpadyS, DoddZH, HavlikRJ, FulkersonDH. Cranial reconstruction for treatment of intracranial hypertension from sclerosteosis: case-based update. World Neurosurg., 2014, 81: 442.e441-442.e445.

[11] FayezA, et al. . A novel loss-of-Sclerostin function mutation in a first Egyptian family with sclerosteosis. Biomed. Res. Int., 2015, 2015. 517815

[12] TacconiP, et al. . Sclerosteosis: report of a case in a black African man. Clin. Genet., 1998, 53: 497-501.

[13] BhadadaSK, et al. . Novel SOST gene mutation in a sclerosteosis patient and her parents. Bone, 2013, 52: 707-710.

[14] Sugiura, Y. & Yasuhara, T. Sclerosteosis. A case report. JBJS57, 273–7 (1975).

[15] HeW-T, et al. . Sclerosteosis caused by a novel nonsense mutation of SOST in a consanguineous family. Clin. Genet., 2016, 89: 205-209.

[16] BalemansW, et al. . Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet., 2001, 10: 537-544.

[17] BrunkowME, et al. . Bone Dysplasia Sclerosteosis results from loss of the SOST gene product, a novel Cystine Knot–containing protein. Am. J. Hum. Genet., 2001, 68: 577-589.

[18] WhyteMP, et al. . Sclerosteosis: Report of type 1 or 2 in three Indian Tamil families and literature review. Bone, 2018, 116: 321-332.

[19] Ekhzaimy, A. A., Alyusuf, E. Y., Alswailem, M. & Alzahrani, A. S. A Novel mutation in a gene causes sclerosteosis in a family of Mediterranean origin. Medicina58, 202 (2022).

[20] BonoF, et al. . Neurological manifestations in patients and disease carriers in an Italian family with osteosclerosis. Neurol. Sci., 2023, 44: 1393-1399.

[21] BalemansW, et al. . Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med. Genet., 2002, 39: 91-97.

[22] LootsGG, et al. . Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res., 2005, 15: 928-935.

[23] Van HulW, et al. . Van Buchem disease (Hyperostosis corticalis generalisata) maps to chromosome 17q12-q21. Am. J. Hum. Genet., 1998, 62: 391-399.

[24] BeightonP, DurrL, HamersmaH. The clinical features of Sclerosteosis. Ann. Intern. Med., 1976, 84: 393-397.

[25] CreminBJ. Sclerosteosis in children. Pediatr. Radio., 1979, 8: 173-177.

[26] BeightonP, HamersmaH. Sclerosteosis in South Africa. South Afr. Med. J., 1979, 55: 783-788

[27] van LieropAH, et al. . Patients with sclerosteosis and disease carriers: Human models of the effect of sclerostin on bone turnover. J. Bone Miner. Res., 2011, 26: 2804-2811.

[28] NagerGT, et al. . Sclerosteosis involving the temporal bone: Clinical and radiologic aspects. Am. J. Otolaryngol., 1983, 4: 1-17.

[29] Hamersma, H. & Hofmeyr, L. in Otosclerosis and Stapes Surgery 65 (S. Karger A. G., 2007).

[30] Potgieter, J. M. et al. An auditory profile of sclerosteosis. J. Laryngol. Otol., 1–9 (2014).

[31] de AndradeEM, Beer-FurlanA, DuarteKP, FonoffET, TeixeiraMJ. Management of trigeminal neuralgia in sclerosteosis. Surg. Neurol. Int., 2013, 4: S455-S459.

[32] SteinSA, et al. . Sclerosteosis: neurogenetic and pathophysiologic analysis of an American kinship. Neurology, 1983, 33: 267-277.

[33] du PlessisJJ. Sclerosteosis: neurosurgical experience with 14 cases. J. Neurosurg., 1993, 78: 388-392.

[34] GardnerJC, et al. . Bone mineral density in sclerosteosis; affected individuals and gene carriers. J. Clin. Endocrinol. Metab., 2005, 90: 6392-6395.

[35] HamersmaH, GardnerJ, BeightonP. The natural history of sclerosteosis. Clin. Genet., 2003, 63: 192-197.

[36] LinC, et al. . Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/β-Catenin signaling. J. Bone Miner. Res., 2009, 24: 1651-1661.

[37] DreyerTJ, KeenJAC, WellsLM, RobertsSJ. Novel insights on the effect of sclerostin on bone and other organs. J. Endocrinol., 2023, 257: e220209.

[38] HoldsworthG, RobertsSJ, KeHZ. Novel actions of sclerostin on bone. J. Mol. Endocrinol., 2019, 62: R167-R185.

[39] NusseR, CleversH. Wnt/β-Catenin signaling, disease, and emerging therapeutic modalities. Cell, 2017, 169: 985-999.

[40] ZhangY, WangX. Targeting the Wnt/β-catenin signaling pathway in cancer. J. Hematol. Oncol., 2020, 13: 165.

[41] LePN, McDermottJD, JimenoA. Targeting the Wnt pathway in human cancers: Therapeutic targeting with a focus on OMP-54F28. Pharmacol. Ther., 2015, 146: 1-11.

[42] GurneyA, et al. . Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc. Natl. Acad. Sci., 2012, 109: 11717-11722.

[43] Funck-BrentanoT, et al. . Porcupine inhibitors impair trabecular and cortical bone mass and strength in mice. J. Endocrinol., 2018, 238: 13-23.

[44] MadanB, et al. . Bone loss from Wnt inhibition mitigated by concurrent alendronate therapy. Bone Res., 2018, 6: 17.

[45] LiuJ, et al. . Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc. Natl. Acad. Sci. USA, 2013, 110: 20224-20229.

[46] FujitaS, et al. . Pharmacological inhibition of tankyrase induces bone loss in mice by increasing osteoclastogenesis. Bone, 2018, 106: 156-166.

[47] LeeE, SalicA, KrügerR, HeinrichR, KirschnerMW. The roles of APC and Axin derived from experimental and theoretical analysis of the Wnt pathway. PLoS Biol., 2003, 1: E10.

[48] ChenX, et al. . Cumulative inactivation of Nell-1 in Wnt1 expressing cell lineages results in craniofacial skeletal hypoplasia and postnatal hydrocephalus. Cell Death Differ., 2020, 27: 1415-1430.

[49] ChungR, et al. . Roles of Wnt/β-catenin signalling pathway in the bony repair of injured growth plate cartilage in young rats. Bone, 2013, 52: 651-658.

[50] GravesenE, et al. . Effect of inhibition of CBP-coactivated β-catenin-mediated Wnt signalling in uremic rats with vascular calcifications. PLoS One, 2018, 13: e0201936.

[51] MorrisA, PagarePP, LiJ, ZhangY. Drug discovery efforts toward inhibitors of canonical Wnt/β-catenin signaling pathway in the treatment of cancer: A composition-of-matter review (2010–2020). Drug Discov. Today, 2022, 27: 1115-1127.

[52] RodonJ, et al. . Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours. Br. J. Cancer, 2021, 125: 28-37.

[53] ChenX, et al. . Osteoblast-osteoclast interactions. Connect. Tissue Res., 2018, 59: 99-107.

[54] DreyerT, et al. . Recombinant sclerostin inhibits bone formation in vitro and in a mouse model of sclerosteosis. J. Orthop. Transl., 2021, 29: 134

[55] WinklerDG, et al. . Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J., 2003, 22: 6267-6276.

[56] AtkinsGJ, et al. . Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J. Bone Miner. Res., 2011, 26: 1425-1436.

[57] LiX, et al. . Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J. Bone Miner. Res., 2008, 23: 860-869.

[58] PereiraAF, JavaheriB, PitsillidesAA, ShefelbineSJ. Predicting cortical bone adaptation to axial loading in the mouse tibia. J. R. Soc. Interface, 2015, 12: 20150590.

[59] StagiS, et al. . Bone metabolism in children and adolescents: main characteristics of the determinants of peak bone mass. Clin. Cases Miner. Bone Metab., 2013, 10: 172-179

[60] Brooke-WavellK, StenselDJ. Exercise and children’s bone health. J. Fam. Health Care, 2008, 18: 205-208

[61] SharmaA, et al. . Sexing bones: improving transparency of sex reporting to address bias within preclinical studies. J. Bone Miner. Res., 2023, 38: 5-13.

[62] LiuJ, et al. . Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct. Target Ther., 2022, 7: 3.

[63] NgM, et al. . First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours. J. Clin. Oncol., 2017, 35: 2584-2584.

[64] FlanaganDJ, WoodcockSA, PhillipsC, EagleC, SansomOJ. Targeting ligand-dependent wnt pathway dysregulation in gastrointestinal cancers through porcupine inhibition. Pharm. Ther., 2022, 238. 108179

[65] ChenB, et al. . Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat. Chem. Biol., 2009, 5: 100-107.

[66] DiegelCR, et al. . Inhibiting WNT secretion reduces high bone mass caused by Sost loss-of-function or gain-of-function mutations in Lrp5. Bone Res., 2023, 11: 47.

[67] MullardA. FDA approves first-in-class osteoporosis drug. Nat. Rev. Drug Discov., 2019, 18: 411

[68] Percie du SertN, et al. . Reporting animal research: explanation and elaboration for the ARRIVE guidelines 2.0. PLOS Biol., 2020, 18: e3000411.

[69] BaoR, et al. . Inhibition of Tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells. PLoS One, 2012, 7: e48670.

[70] LiK, et al. . Geraniin promotes osteoblast proliferation and differentiation via the activation of Wnt/β-catenin pathway. Biomed. Pharmacother., 2018, 99: 319-324.

[71] TrossetJY, et al. . Inhibition of protein-protein interactions: the discovery of druglike beta-catenin inhibitors by combining virtual and biophysical screening. Proteins, 2006, 64: 60-67.

[72] DeshmukhV, et al. . A small-molecule inhibitor of the Wnt pathway, lorecivivint (SM04690), as a potential disease-modifying agent for the treatment of degenerative disc disease. Spine J., 2020, 20: 1492-1502.

[73] TaylorSE, ShahM, OrrissIR. Generation of rodent and human osteoblasts. Bonekey Rep., 2014, 3: 585.

[74] OrrissIR, ArnettTR. Rodent osteoclast cultures. Methods Mol. Biol., 2012, 816: 103-117.

[75] O’BrienJ, WilsonI, OrtonT, PognanF. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur. J. Biochem., 2000, 267: 5421-5426.

[76] LeungKS, FungKP, SherAH, LiCK, LeeKM. Plasma bone-specific alkaline phosphatase as an indicator of osteoblastic activity. J. Bone Jt. Surg. Br., 1993, 75: 288-292.

[77] KeHZ, RichardsWG, LiX, OminskyMS. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr. Rev., 2012, 33: 747-783.

[78] YangH, et al. . Cortical bone adaptation to a moderate level of mechanical loading in male Sost deficient mice. Sci. Rep., 2020, 10. 22299

[79] MorseA, et al. . Mechanical load increases in bone formation via a sclerostin-independent pathway. J. Bone Miner. Res, 2014, 29: 2456-2467.

[80] De SouzaRL, et al. . Non-invasive axial loading of mouse tibiae increases cortical bone formation and modifies trabecular organization: a new model to study cortical and cancellous compartments in a single loaded element. Bone, 2005, 37: 810-818.

Funding

UCB Pharma, 216 Bath Road, Slough, United Kingdom, SL1 3WE. Grant recipient is Scott Roberts.

RIGHTS & PERMISSIONS

The Author(s)